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Abstract 
A 13-year-old girl with a remote history of juvenile pilocytic astrocytoma developed acute 
onset flushing, tachycardia and shortness of breath immediately following administration of 
gadopentetate dimeglumine during routine brain MRI that subsided following intravenous 
diphenhydramine. A retrospective review of the MRI results revealed multiple areas of 
contrast enhancement of the face, consistent with observed urticaria. The patient received 
pretreatment medications prior to subsequent gadolinium injections without incident. 
Gadolinium allergy is extremely rare and has been reported in less than 0.1% of injections. 
However, in patients who undergo anesthesia for MRI studies, similar subtle extracranial 
MRI findings should alert the neuroradiologist to possible gadolinium allergy that may 
warrant premedication prior to future injections. 
 
Introduction 
Gadolinium contrast agents have been safely used in children and adults for over 20 
years. The incidence of gadolinium allergy in children is between 0.04 and 0.1%, based 
on published case series [1–3]. In those patients with central nervous system tumors, 
gadolinium contrast injection is absolutely necessary to monitor disease status. We 
report a case of a 13-year-old girl, with a history of low-grade glioma, who developed 
shortness of breath and urticaria following injection of intravenous gadolinium while in 
the MRI scanner. The incidental MRI findings reported may assist in recognizing 
gadolinium allergy in younger patients who are under anesthesia during their 
neuroimaging studies.  
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Case Report 
A 13-year-old girl, diagnosed with a posterior fossa juvenile pilocytic astrocytoma, status post 
gross total resection 1 year prior, underwent routine MRI neuroimaging with and without gadolinium. 
Following an injection of intravenous gadopentetate dimeglumine, she developed acute onset 
flushing, tachycardia and shortness of breath. The patient was promptly removed from the MRI 
scanner and given intravenous diphenhydramine, after which she quickly returned to baseline. Her 
physical examination was notable for diffuse urticaria that resolved following treatment. Neurological 
examination showed no deficits. She had no prior history of allergic reactions and no known allergy 
risk factors. Brain MRI initially reported stable post-operative changes and no evidence of residual 
neoplasm. However, on retrospective review in light of the history, several extracranial areas of 
abnormality were discovered, as shown in fig. 1. The post-gadolinium MRI revealed multiple areas of 
contrast-enhancing soft tissue lesions of the bilateral face consistent with the observed urticaria. 
Additionally, there was an area of contrast enhancement of the right ear. The patient has had 
subsequent MRI evaluations with gadolinium following pretreatment with corticosteroids and 
antihistamines without incident and with complete resolution of the aforementioned findings. 
Conclusions 
Our reported MRI findings of post-gadolinium hypersensitivity are admittedly 
coincidental; however, recognition of gadolinium allergy can be critical. Severe 
anaphylactoid reactions and even death have been well described in the literature [1–
14]. Dillman et al. [1] reported a gadolinium allergy incidence of 0.4% in their pediatric 
population and a 7% overall incidence of severe reactions. Patients can have allergic 
reactions to gadolinium compounds in spite of pretreatment with antihistamines and 
corticosteroids [14]. Those patients with a prior history of allergic reaction to iodinated 
compounds may be at risk for reactions to gadolinium [15]. In the case of our patient, 
she had had several previous injections without incident and had no prior history of 
allergic reactions. Our case illustrates extracranial manifestations of gadolinium allergy 
that may alert the neuroradiologist, particularly in cases where patients are under 
anesthesia and may have less subtle findings. 
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Fig. 1. MRI findings of gadolinium hypersensitivity. Coronal (a) and axial (b) post-contrast MRI brain 
sequences reveal multiple areas of superficial gadolinium enhancement (arrows) and right-sided 
auricular enhancement following administration of intravenous gadopentetate dimeglumine. 
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